Determinação do clearance de ácidos graxos voláteis na digesta ruminal intacta
DOI:
https://doi.org/10.21615/cesmvz.14.1.1Resumen
Cannulated cows were allocated to a cross-over design to evaluate the technique
for determination of volatile fatty acid (VFA) clearance by infusion of marker solution into intact ruminal digesta, and verify the technique sensibility to the variation in the diet. Animals received diet of forage or forage plus concentrate and infusion of valeric acid and Cr-EDTA solution into intact or evacuated ruminal digesta. The total fractional rate of VFA clearance (FRVFAC) was estimated by the exponential decay of valerate over time. The passage FRVFAC to the omasum was assumed as the decay in ruminal Cr concentration and the absorption FRVFAC was estimated by the difference. The total FRVFAC and absorption did not differ between techniques. The passage FRVFAC, however, was lower when the marker solution was added into the evacuated digesta, probably reflecting the destabilization of the rumen environment during the evacuation and the largest volume of fluid observed in animals with evacuated digesta. In conclusion, the infusion of marker solution into intact digesta with homogenization performed by ruminal motility could be usable for the VFA ruminal clearance determination since it seems to cause lesser disturbance in the ruminal environment.
Determination of volatile fatty acids clearance in intact ruminal digesta
Los bovinos canulados fueron asignados en un delineamiento cruzado para evaluar la técnica de determinación del clearance de ácidos grasos volátiles (VFA) por infusión de solución marcadora en la digesta ruminal intacta, y verificado la sensibilidad de la técnica a la variación en la dieta. Los animales recibieron dieta de forraje o forraje junto con concentrado e infusión de ácido valérico y solución de Cr-EDTA en la digesta ruminal intacta o evacuada. La tasa fraccional total de depuración de AGV (FRVFAC) fue estimada por el decaimiento exponencial del valerato a lo largo del tiempo. El pasaje FRVFAC para el omaso fue asumido como el decaimiento en la concentración ruminal de Cr y la absorción FRVFAC fue estimada por la diferencia. La FRVFAC total y la absorción no difirieron entre las técnicas. El paso FRVFAC, sin embargo, fue menor cuando la solución marcadora fue agregada en la digestión eva- cuada, probablemente reflejando la desestabilización del ambiente ruminal durante la evacuación y el mayor volumen de líquido observado en animales con digestión evacuada. En conclusión, la infusión de la solución marcadora en la digesta intacta con homogeneización realizada por la motilidad ruminal podría ser utilizada para la determinación de la depuración ruminal de la VFA, ya que parece causar menor disturbio en el ambiente ruminal.
Keywords: acidosis, Cr-EDTA, fisiología ruminal, estómago.
Determinação do clearance de ácidos graxos voláteis na digesta ruminal intacta
Bovinos canulados foram alocados em um delineamento cruzado para avaliar
a técnica de determinação do clearance de ácidos graxos voláteis (VFA) por infusão de solução marcadora na digesta ruminal intacta, e verificado a sensibilidade da técnica à variação na dieta. Os animais receberam dieta de forragem ou forragem juntamente com concentrado e infusão de ácido valérico e solução de Cr-EDTA na digesta ruminal intacta ou evacuada. A taxa fracional total de depuração de AGV (FRVFAC) foi estimada pelo decaimento exponencial do valerato ao longo do tempo. A passagem FRVFAC para o omaso foi assumida como o decaimento na concentração ruminal de Cr e a absorção FRVFAC foi estimada pela diferença. A FRVFAC total e a absorção não diferiram entre as técnicas. A passagem FRVFAC, entretanto, foi menor quando a solução marcadora foi adicionada na digesta evacuada, provavelmente refletindo a desestabilização do ambiente ruminal durante a evacuação e o maior volume de líquido observado em animais com digesta evacuada. Em conclusão, a infusão da solução marcadora na digesta intacta com homogeneização realizada pela motilidade ruminal poderia ser utilizada para a determinação da depuração ruminal de VFA, uma vez que parece causar menor distúrbio no ambiente ruminal.
Palavras-chave: acidose, Cr-EDTA, fisiologia ruminal, estômago.
Descargas
Referencias bibliográficas
Mutsaers AJ. Chemotherapy: new uses for old drugs. Vet Clin North Am Small Anim Pract 2007; 37(6): 1079 – 1090.
Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, et al. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013; 6(5): 511 – 519.
Biller B. Metronomic chemotherapy in veterinary patients with cancer. Vet Clin North Am Small Anim Pract 2014; 44(5): 817 – 829.
Pang LY, Argyle DJ. Veterinary oncology: biology, big data and precision medicine. Vet J 2016; 213: 38 – 45.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893 – 2917.
Breen M. Update on Genomics in veterinary oncology. Top Companion Anim Med 2009; 24(3): 113 – 121.
Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000; 100: 57 – 70.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646 – 674.
Withrow SJ, Vale DM, Page R. Withrow and MacEwen’s Small Animal Clinical Oncology. 5ª ed. [S.l.]: Saunders Elsevier; 2012.
Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol 2015; 95(1): 46 – 61.
Takimoto CH. Maximum tolerated dose: clinical endpoint for a bygone era? Target Oncol 2009; 4(2): 143 – 147.
Hanahan D, Bergers G, Bergsland E. Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105(8): 1045 – 1047.
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4(6): 423 – 436.
Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7(8): 455 – 465.
Chen C, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014; 16(1): 84 – 96.
Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today 2013; 18(3-4): 193 – 201.
Mutsaers AJ. Metronomic Chemotherapy. Top Companion Anim Med 2009; 24(3): 137 – 143.
Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Investig 2012; 92(7): 952 – 966.
Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 2008; 7(1): 79 – 89.
Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7(11): 834 – 846.
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23(8): 8–11.
Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 2013; 49(16): 3387 – 3395.
Shi H, Jiang J, Ji J, Shi M, Cai Q, et al. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Cancer Lett 2014; 349(2): 128 – 135.
Penel N, Adenis A, Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 2012; 82(1): 40 – 50.
Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 2016; 13: 1 – 15.
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22(3): 659 – 661.
Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13(1): 73 – 80.
Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006; 6: 225.
Khan OA, Blann AD, Payne MJ, Middleton MR, Protheroe AS, et al. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer 2011; 104(12): 1822 – 1827.
Jung JY, Jang G, Song H, Kim HS, Choi DR, et al. Efficacy of metronomic chemotherapy with oral cyclophosphamide and methotrexate in patients with non-Hodgkin lymphoma: a retrospective analysis at a single institution. Int J Clin Exp Med 2016; 9(2): 3893 – 3900.
Jang JW, Park SR, Kwon JH, You CR, Choi JY, et al. Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma. Exp Mol Med 2001; 43(5): 305 – 312.
Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012; 75(2): 1103 – 1115.
Rozados VR, Sánchez AM, Gervasoni SI, Berra HH, Matar P, et al. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol 2004; 15(10): 1543 – 1550.
Burton JH, Mitchell L, Thamm DH, Dow SW, Biller BJ. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J Vet Intern Med 2011; 25(4): 920 – 926.
Mitchell L, Thamm DH, Biller BJ. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med 2012; 26(2): 355 – 362.
Lana S, U’ren L, Plaza S, Elmslie R, Gustafson D, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007; 21: 764 – 769.
Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008; 22(6): 1373 – 1379.
Tripp CD, Fidel J, Anderson CL, Patrick M, Pratt C, et al. Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 2011; 25(2): 278 – 284.
Marchetti V, Giorgi M, Fioravanti A, Finotello R, Citi S, et al. First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Invest New Drugs 2012; 30(4): 1725 – 1730.
Schrempp DR, Childress MO, Stewar JC, Tan KM, Gortari AE, et al. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. J Am Vet Med Assoc 2013; 242(11): 1534 – 1538.
Leo, C, Stell A, Borrego J, Martinez de Merlo E, Ruess-Melzer K, et al. Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia. J Feline Med Surg 2014; 16(8): 671 – 678.
André N, Abed S, Orbach D, Alla CA, Padovani L, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011; 2(12): 960 – 965.
Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M. Metronomic therapy and breast cancer: a systematic review. Cancer Treat Rev 2014; 40(8): 942 – 950.
Livshits Z, Rao RB, Smith SW. An approach to chemotherapy – associated toxicity. Emerg Med Clin N Am 2014; 32(1): 167 – 203.
Emmenegger U, Man S, Shaked Y, Francia J, Wong JW, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004; 64(11): 3994 – 4000.
Jalali AS, Hasanzadeh S, Malekinejad H. Achillea millefolium inflorescence aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences. Chin J Nat Med 2012; 10(4): 247 – 254.
Senthilkumar S, Devaki T, Manohar BM, Babu MS. Effect of squalene on cyclophosphamide-induced toxicity. Clin Chim Acta 2005; 364(1-2): 335 – 342.
Viéra RB, Correal ML, Sierra OS, Martinato F, Santos MQP, et al. Cistite hemorrágica estéril por uso de ciclofosfamida em cão: relato de caso. JBCA (Anais do Onco in Rio) 2016; S: 7-10.
Masci G, Losurdo A, Gandini C, Garassino I, Di Tomasso L, et al. Low-dose ‘metronomic chemotherapy’ with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit. Ecancer Medical Science 2012; 6(1): 1–5.
Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, et al. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev 13: 1109 – 1113.
Maggo G, Grover SC, Grin A. Capecitabine induced colitis. Pathol - Res Pract 2014; 210(9): 606 – 608.
Saba, Khan S, Parvez S, Chaudhari B, Ahmad F, et al. Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats. Food Chem Toxicol 2013; 58: 210 – 219.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
